Well, Vertex has posted its first quarterly profit in company history, due to ferocious uptake in the next-gen Hep C drug triple therapy regimen spear-headed by Vertex’s telaprevir (branded as Incivek®) — thus, per Reuters, just now:
. . . .Vertex. . . reported its first ever quarterly profit and said that its Incivek hepatitis C treatment had sales of nearly $420 million in the first full quarter on the market, making for one of the most impressive new drug launches in history.
Incivek, which was approved in May, is on track to easily surpass $1 billion in sales in its first year on the market.
“It looks like it’s the best launch of all time in the history of biotech and pharma,” said ISI Group analyst Mark Schoenebaum.
Vertex’s first commercial product is fast becoming part of the standard of care for the serious liver disease as it competes with a similar new medicine from Merck that also received U.S. approval in May. . . .
Vertex sales beat even the loftiest analysts’ projections this quarter. Let’s see if Merck’s Victrelis® will project reaching $1 billion in sales in 2011, come tomorrow morning. Hint: Not likely.